Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.79 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.79 |
| ▸ | MERTK | Q12866 | 1/20 | 0.79 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.79 |
| ▸ | AXL | P30530 | 1/20 | 0.79 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dezapelisib SCHEMBL960769 | 1.00 | PIK3CD (0.79) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL29487623 | 1.00 | PIK3CD (0.79) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL29487633 | 1.00 | PIK3CD (0.79) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL977259 | 1.00 | PIK3CD (0.79) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL18228627 | 0.99 | PIK3CD (0.78) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL18300317 | 0.99 | PIK3CD (0.78) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL18301014 | 0.96 | PIK3CD (0.74) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL18301013 | 0.96 | PIK3CD (0.74) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL1001069 | 0.95 | PIK3CD (0.72) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Dezapelisib SCHEMBL974165 | 0.95 | PIK3CD (0.72) | PIK3CDPIK3CGMERTKPIK3R1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2023285681-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SPEXIS AG (CH) | 2023-01-19 | — | — | WO | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | claimed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | claimed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | claimed |
| US-20160362425-A1 | CRYSTALLINE FORMS OF A PI3K INHIBITOR | INCYTE CORPORATION | 2016-12-15 | — | — | US | claimed |
| US-9434746-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2016-09-06 | — | — | US | claimed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | claimed |
| EP-2448938-B9 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2015-06-10 | — | — | EP | claimed |
| EP-2845856-A1 | Pyrimidinones as PI3K inhibitors | Incyte Corporation (US) | 2015-03-11 | — | — | EP | claimed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | claimed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | claimed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | claimed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885PIK3CG 13/4885MERTK 452/4885 |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | PIK3CD 1398/4885PIK3CG 1204/4885MERTK 2620/4885 |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20160362425-A1 | CRYSTALLINE FORMS OF A PI3K INHIBITOR | PIK3CA, PIK3CD, PIK3CG | PIK3CD 2/4885PIK3CG 3/4885MERTK 896/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885PIK3CG 13/4885MERTK 452/4885 |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | PIK3CD 107/4885PIK3CG 123/4885MERTK 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.